Heartbeam, Inc. Common Stock (BEAT) Stock Price
BEATStock
$0.44−74.80%52W
Market Cap$24.57M
P/E—
PEG Ratio—
Div yield—
Beta-0.87
BEAT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-73.57%
Price vs S&P 500 (4W)2.49%
VGM Score33.20
BEAT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.09 | -$0.10 | -11.11%(-$0.01) | |
| Q1 2026 | -$0.14 | -$0.12 | +11.11%(+$0.02) | |
| Q4 2025 | -$0.14 | -$0.14 | -1.82%(-$0.00) | |
| Q3 2025 | -$0.15 | -$0.15 | +3.23%(+$0.01) | |
| Q2 2025 | -$0.16 | -$0.15 | +6.25%(+$0.01) |
BEAT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.11
4.11
4.10
4.11
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BEATHeartbeam, Inc. Common Stock | — | — | D | — | — | — | — | $0.44 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Heartbeam, Inc. Common Stock
HeartBeam develops ambulatory ECG solutions using proprietary Vector Electrocardiography (VECG) technology to enable cardiac disease detection and monitoring outside traditional healthcare settings. The company's validated platform provides higher-resolution remote monitoring capabilities for telehealth applications. HeartBeam is pursuing FDA clearance for its initial telehealth products.